Trending: Investing in Bitcoin / 5 reasons to invest in Amazon / Investing in the Metaverse
Wednesday, March 22, 2023
INVESTOR TIMES
  • Home
  • News
    How much will the fight with Kanye West cost Adidas?

    How much will the fight with Kanye West cost Adidas?

    TD Cowen: SVB’s fall does not threaten the stability of the banking system

    TD Cowen: SVB’s fall does not threaten the stability of the banking system

    Public investment in Ireland will be only for sustainable businesses

    Public investment in Ireland will be only for sustainable businesses

    Jerome Powell warns Fed could raise rates further

    Jerome Powell warns Fed could raise rates further

    JPMorgan: “zero-day” options contracts would sink SPX

    JPMorgan: “zero-day” options contracts would sink SPX

    Used cars prices rise unusually in the U.S

    Used cars prices rise unusually in the U.S

    Chinese mobile manufacturers want to go after Apple and Samsung

    Chinese mobile manufacturers want to go after Apple and Samsung

    ACS to build a battery plant for Panasonic in the U.S

    ACS to build a battery plant for Panasonic in the U.S

    Carvana could be on the verge of bankruptcy

    Carvana could be on the verge of bankruptcy

  • Markets
    Pontegadea continues to buy real estate: now the target is London

    Pontegadea continues to buy real estate: now the target is London

    BMW adds to profits thanks to Rolls Royce and Mini

    BMW adds to profits thanks to Rolls Royce and Mini

    Puma achieves record sales in last year with Gulden as CEO

    Puma achieves record sales in last year with Gulden as CEO

    Nike and Decathlon lead as the world’s largest sports retailers

    Nike and Decathlon lead as the world’s largest sports retailers

    Walmart unstoppable: sells U$S 611 billion in 2022

    Walmart unstoppable: sells U$S 611 billion in 2022

    Experts: recession to come at the end of rate hike cycle

    Experts: recession to come at the end of rate hike cycle

    Is it time to bet on tech stocks again?

    Is it time to bet on tech stocks again?

    Is it better to invest in Stellantis or in Ford and GM?

    Is it better to invest in Stellantis or in Ford and GM?

    U.S. housing market could continue to decline

    U.S. housing market could continue to decline

  • Investing
    Hedging hurts more than stock market declines, study says

    Hedging hurts more than stock market declines, study says

    How to manage risk in times of stock market volatility

    How to manage risk in times of stock market volatility

    Gold investment price

    Why a physical gold IRA is becoming a hot investing topic

    Home Depot announces dividend increase

    Home Depot announces dividend increase

    The fall in Alibaba’s earnings softens

    The fall in Alibaba’s earnings softens

    Is it better to invest in Stellantis or in Ford and GM?

    Is it better to invest in Stellantis or in Ford and GM?

    The biggest investment mistakes made by Warren Buffett

    The biggest investment mistakes made by Warren Buffett

    Which stocks are attractive for investing in IoT and robotics

    Which stocks are attractive for investing in IoT and robotics

    Mixed results for Uber Technologies in 2022

    Mixed results for Uber Technologies in 2022

  • Technology
    Why Americans want to remove Instagram from their phones

    Why Americans want to remove Instagram from their phones

    Tesla prepares a Model Y update: what we know about “Juniper”

    Tesla prepares a Model Y update: what we know about “Juniper”

    Li-Cycle to recycle lithium batteries in Rochester

    Li-Cycle to recycle lithium batteries in Rochester

    Is it time to bet on tech stocks again?

    Is it time to bet on tech stocks again?

    Amazon goes all-in on live sports streaming

    Amazon goes all-in on live sports streaming

    Bing’s AI has “lost its mind”

    Bing’s AI has “lost its mind”

    ChatGPT’s Chinese competitor to be launched in March

    ChatGPT’s Chinese competitor to be launched in March

    Alphabet board confesses doubts about Bard

    Alphabet board confesses doubts about Bard

    Advantages and disadvantages of AI, according to Bill Gates

    Advantages and disadvantages of AI, according to Bill Gates

  • CryptocurrenciesTRENDING
    Circle’s exposure to SVB is $3.3 billion

    Circle’s exposure to SVB is $3.3 billion

    Crypto crisis drives Silvergate into bankruptcy

    Crypto crisis drives Silvergate into bankruptcy

    Censorship resistance: what is it and why is it so important in the crypto industry?

    Censorship resistance: what is it and why is it so important in the crypto industry?

    Forbes claims Binance is in trouble, Zhao denies it

    Forbes claims Binance is in trouble, Zhao denies it

    SEC reportedly preparing a battle against stablecoins

    SEC reportedly preparing a battle against stablecoins

    U.S. regulatory pressure on cryptomarket increases

    U.S. regulatory pressure on cryptomarket increases

    What is Crypto Staking and why is the SEC regulating these services?

    What is Crypto Staking and why is the SEC regulating these services?

    Shanghai: a glimpse of Ethereum’s next update

    Shanghai: a glimpse of Ethereum’s next update

    Manchester City token collapses for this reason

    Manchester City token collapses for this reason

S&P 500 (USA) 
4.002.87  51.30  1.30%  
NASDAQ Composite (USA) 
11.860.11  184.57  1.58%  
Dow Jones (USA) 
32.560.60  316.02  0.98%  
FTSE 100 (United Kingdom) 
7.516.77  19.45  0.26%  
EURO STOXX 50 (Europe) 
4.174,66  6,94  0,00%  
Nikkei 225 
27.466.61  520.94  1.93%  
VIX 
22.12  2.03  8.41%  
Bitcoin (USD) 
28.198.93  555.59  2.01%  
Ethereum (USD) 
1.792.67  54.71  3.15%  
  • Home
  • News
    How much will the fight with Kanye West cost Adidas?

    How much will the fight with Kanye West cost Adidas?

    TD Cowen: SVB’s fall does not threaten the stability of the banking system

    TD Cowen: SVB’s fall does not threaten the stability of the banking system

    Public investment in Ireland will be only for sustainable businesses

    Public investment in Ireland will be only for sustainable businesses

    Jerome Powell warns Fed could raise rates further

    Jerome Powell warns Fed could raise rates further

    JPMorgan: “zero-day” options contracts would sink SPX

    JPMorgan: “zero-day” options contracts would sink SPX

    Used cars prices rise unusually in the U.S

    Used cars prices rise unusually in the U.S

    Chinese mobile manufacturers want to go after Apple and Samsung

    Chinese mobile manufacturers want to go after Apple and Samsung

    ACS to build a battery plant for Panasonic in the U.S

    ACS to build a battery plant for Panasonic in the U.S

    Carvana could be on the verge of bankruptcy

    Carvana could be on the verge of bankruptcy

  • Markets
    Pontegadea continues to buy real estate: now the target is London

    Pontegadea continues to buy real estate: now the target is London

    BMW adds to profits thanks to Rolls Royce and Mini

    BMW adds to profits thanks to Rolls Royce and Mini

    Puma achieves record sales in last year with Gulden as CEO

    Puma achieves record sales in last year with Gulden as CEO

    Nike and Decathlon lead as the world’s largest sports retailers

    Nike and Decathlon lead as the world’s largest sports retailers

    Walmart unstoppable: sells U$S 611 billion in 2022

    Walmart unstoppable: sells U$S 611 billion in 2022

    Experts: recession to come at the end of rate hike cycle

    Experts: recession to come at the end of rate hike cycle

    Is it time to bet on tech stocks again?

    Is it time to bet on tech stocks again?

    Is it better to invest in Stellantis or in Ford and GM?

    Is it better to invest in Stellantis or in Ford and GM?

    U.S. housing market could continue to decline

    U.S. housing market could continue to decline

  • Investing
    Hedging hurts more than stock market declines, study says

    Hedging hurts more than stock market declines, study says

    How to manage risk in times of stock market volatility

    How to manage risk in times of stock market volatility

    Gold investment price

    Why a physical gold IRA is becoming a hot investing topic

    Home Depot announces dividend increase

    Home Depot announces dividend increase

    The fall in Alibaba’s earnings softens

    The fall in Alibaba’s earnings softens

    Is it better to invest in Stellantis or in Ford and GM?

    Is it better to invest in Stellantis or in Ford and GM?

    The biggest investment mistakes made by Warren Buffett

    The biggest investment mistakes made by Warren Buffett

    Which stocks are attractive for investing in IoT and robotics

    Which stocks are attractive for investing in IoT and robotics

    Mixed results for Uber Technologies in 2022

    Mixed results for Uber Technologies in 2022

  • Technology
    Why Americans want to remove Instagram from their phones

    Why Americans want to remove Instagram from their phones

    Tesla prepares a Model Y update: what we know about “Juniper”

    Tesla prepares a Model Y update: what we know about “Juniper”

    Li-Cycle to recycle lithium batteries in Rochester

    Li-Cycle to recycle lithium batteries in Rochester

    Is it time to bet on tech stocks again?

    Is it time to bet on tech stocks again?

    Amazon goes all-in on live sports streaming

    Amazon goes all-in on live sports streaming

    Bing’s AI has “lost its mind”

    Bing’s AI has “lost its mind”

    ChatGPT’s Chinese competitor to be launched in March

    ChatGPT’s Chinese competitor to be launched in March

    Alphabet board confesses doubts about Bard

    Alphabet board confesses doubts about Bard

    Advantages and disadvantages of AI, according to Bill Gates

    Advantages and disadvantages of AI, according to Bill Gates

  • CryptocurrenciesTRENDING
    Circle’s exposure to SVB is $3.3 billion

    Circle’s exposure to SVB is $3.3 billion

    Crypto crisis drives Silvergate into bankruptcy

    Crypto crisis drives Silvergate into bankruptcy

    Censorship resistance: what is it and why is it so important in the crypto industry?

    Censorship resistance: what is it and why is it so important in the crypto industry?

    Forbes claims Binance is in trouble, Zhao denies it

    Forbes claims Binance is in trouble, Zhao denies it

    SEC reportedly preparing a battle against stablecoins

    SEC reportedly preparing a battle against stablecoins

    U.S. regulatory pressure on cryptomarket increases

    U.S. regulatory pressure on cryptomarket increases

    What is Crypto Staking and why is the SEC regulating these services?

    What is Crypto Staking and why is the SEC regulating these services?

    Shanghai: a glimpse of Ethereum’s next update

    Shanghai: a glimpse of Ethereum’s next update

    Manchester City token collapses for this reason

    Manchester City token collapses for this reason

INVESTOR TIMES
Home Investing

Two biotech stocks that could explode soon

Less than $10 can buy each share of these companies. Why are they special? Because the FDA may soon approve their drugs.

Alejandro Gil by Alejandro Gil
12/13/2022 - 16:31
in Investing
Reading Time: 4 mins read
Share on FacebookShare on TwitterShare on LinkedIn
  • Stocks of companies in the biotechnology sector are characterized by their attractiveness, regardless of the financial climate.
  • If these companies have key research on a drug that radically changes a health condition, they have a plus.
  • This paper presents two such companies that could generate significant returns if bought now.

In a recent article, we presented some investment options in technology companies that could make a difference. However, the sector is not without risk for many investors with low risk tolerance. If that is the case, two biotech stocks that could deliver significant returns with lower chances of failure are now presented.

The cardinal point here is that companies linked to the healthcare sector will always be of relevance. The latter is as true in times of bull markets as it is in times of recession. People need advances in medical science in any scenario and that is when technological developments in which some companies excel appear.

For investors, knowing those companies and what their jobs and potential are is one of the key tasks for success. In this paper we present two companies that are currently developing drugs that could be transcendental. Also, if they receive approval from the Food and Drug Administration (FDA), their shares could take a giant leap forward. The good news: both are under $10 per share.

Some clarification on biotech stocks

As stated earlier, biotech stocks are low-cost and there will always be demand for these companies’ products. However, there are “buts” that investors should consider before making any decisions. In this case, it should not be overlooked that the products of these companies do not resemble those of others in terms of timing.

“Successful investments in biopharma companies are not always short-range and the road is often fraught with setbacks.”

For example, for companies like Samsung, a defective cell phone released to the market is picked up again to tweak it. That scenario is negated for companies involved in the health area and the reasons are obvious. In that sense, the FDA will not license drugs that have not passed all phases of clinical trials.

The latter translates into time. In other words, investments in the sector are not for the impatient or for people with weak nerves. Pharmaceutical companies’ products often take years or even decades before advancing from one phase to the next, especially for pathologies that harm millions of people every year. Add to this the setbacks that some of these companies often face due to unfair competition or conspiracy theories.

Either way, the shares of biotech companies are a veritable roller coaster that is barely surpassed by some cryptocurrencies. Meanwhile, the late deliveries and negative quarterly results that companies always drag along are a headache for unprepared investors.

That said, it should be added that waiting and endurance provide rewards like no other. The returns offered by the shares of some companies in the sector can change completely with just one approval from U.S. regulators.

These are the two biotech stocks that could be hidden gems

Knowing the context of investing in companies in the sector, it should be noted that the risks are considerable. But a varied and well-ordered portfolio of pharmaceutical companies will always be, if I may say so, healthy. These are the two companies that could become the next source of returns for your investors:

  1. TG Therapeutics (TGTX).
  2. Acer Therapeutics (ACER)

There are three basic elements that determine that the shares of a company in the sector will enter an uptrend. These are positive clinical trial results, potential regulatory agency approval and the launch of a new drug to combat a pathology. If at least two of these catalysts come together, the chances of success are almost certain.

Even if some companies are in the midst of a long lead time for their products, one of these three elements would be enough to drive the stock price higher. That means those three catalysts have mechanics that are not subject to market conditions, which is good news for investors.

The latter translates into biotech stocks potentially starting a rally against the tide. The two companies cited for this paper received praise from analysts. The data for these two companies was taken from TipRanks and cross-checked with other portals such as Yahoo Finance.

1. TG Therapeutics

TG stands out among shares of biotechnology companies
Image: Finance.yahoo.com

This biopharmaceutical research company specializes in creating new treatments for B-cell diseases. These are serious autoimmune conditions. They are characterized by a loss of B-cell tolerance and inadequate production of certain antibodies. Among the most common manifestations of this condition are multiple sclerosis and rheumatoid arthritis.

The key element of TG that captivates analysts is that it has a huge pipeline of options for these diseases. Some of the likely drugs are in early stage clinical trials and one of them is on the frontier of FDA approval.

This is ublituximab, which is “a glycoengineered monoclonal antibody designed to target a ‘single epitope on CD20-expressing B cells,'” TipRanks says. This drug recently completed two Phase 3 trials (Ultimate I and II). Based on the results obtained, the company felt confident to apply for an FDA biologics license. By December 28, 2022, the company would meet the requirements for acceptance by the regulatory agency.

This drug is the company’s big news and would be preparing for a commercial launch in early 2023. If the drug is finally approved, the company’s shares would be at the top of the biotechnology sector in a few weeks.

Some analysts such as Ladenburg’s Matt Kaplan – consulted on the aforementioned portal – are extremely bullish. He believes that the company’s shares will reach $22 dollars from now until one year from now. This is a 168% growth considering that the current price is $8.56 dollars per share, according to Yahoo Finance.

Four other Wall Street analysts are fully betting on buying the stock, giving it a “strong buy” rating. The consensus places a price target of $19.75 per share.

2. Acer Therapeutics

ACER is another of the sector's strongest bets
Image: Finance.yahoo.com

The second of these companies is no slouch in terms of its projects and potential for share growth. Acer is focused on fighting serious metabolic diseases, particularly those conditions that due to their rarity do not have appropriate medical treatments. The company has three strong drug candidates. Among them, the most advanced is ACER-001.

This remedy is based on the treatment of inborn errors of metabolism, TipRanks explains. Among the diseases it neutralizes are urea cycle disorders, OTCs and maple syrup-smelling urine disease (MSUD). The latter is a rare condition in some infants and is caused by the body’s inability to break down some parts of proteins.

The FDA license application was resubmitted in July of this year and the cycle is expected to be completed by the end of January 2023. Although the application has already been rejected, the regulatory agency itself clarified that it was not a matter of problems with the drug, but of infrastructure and other protocols.

In any case, the reports of the aforementioned media say that within the company, optimism is exultant. This is evidenced by the fact that the CEO himself, Steven Lisi, has reportedly bought more than 819,836 shares of the company. Similarly, the firm’s president also purchased 409,836 shares at a cost of $500,000. Optimism is also expressed by Wall Street analysts.

Out of four analysts consulted by the portal, all of them are betting on a solid buy vote and none of them thinks that it would be a good option to sell or sell. Thus, the rating is “strong buy”. The price target for the stock is $9.67 per unit. At Monday’s close, the stock was trading at $2.9, up 37% in 24 hours. Nearly 500% would be the stock’s growth a year from now, according to analysts.

Thus, the shares of these biotech companies are emerging as two winning options.

This work is not investment advice. Its content is merely informative.

Tags: BiotechnologyFDAhealthsharesStock exchange

Related articles

Hedging hurts more than stock market declines, study says
Investing

Hedging hurts more than stock market declines, study says

by Alejandro Gil
— March 15, 2023
How to manage risk in times of stock market volatility
Investing

How to manage risk in times of stock market volatility

by Santiago Contreras
— March 9, 2023
Gold investment price
Investing

Why a physical gold IRA is becoming a hot investing topic

by David Romero
— March 9, 2023
Home Depot announces dividend increase
Investing

Home Depot announces dividend increase

by Alejandro Gil
— March 3, 2023
The fall in Alibaba’s earnings softens
Investing

The fall in Alibaba’s earnings softens

by Pablo Petovel
— March 2, 2023

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Last published articles

How much will the fight with Kanye West cost Adidas?
News

How much will the fight with Kanye West cost Adidas?

by Pablo Petovel
— March 16, 2023
Pontegadea continues to buy real estate: now the target is London

Pontegadea continues to buy real estate: now the target is London

by Pablo Petovel
  March 16, 2023

BMW adds to profits thanks to Rolls Royce and Mini

BMW adds to profits thanks to Rolls Royce and Mini

by Pablo Petovel
  March 15, 2023

TD Cowen: SVB’s fall does not threaten the stability of the banking system

TD Cowen: SVB’s fall does not threaten the stability of the banking system

by Alejandro Gil
  March 15, 2023

Hedging hurts more than stock market declines, study says

Hedging hurts more than stock market declines, study says

by Alejandro Gil
  March 15, 2023

Facebook Twitter LinkedIn Telegram RSS

ABOUT INVESTOR TIMES

INVESTOR TIMES is an independent publication of economic, finance and investment content, owned and operated by Altas Ventures.

MORE ABOUT US

  • Our team
  • Work with us
  • Advertise on IT
  • Contact
  • Corporate information
  • Terms of Use
  • Cookies Policy
  • Privacy Policy

INTERNATIONAL EDITIONS

Investor Times in English

Investor Times en Français

Investor Times in Deutsch

Investor Times in Italiano

Investor Times em Português

Investor Times po Polsku

Investor Times на русском языке

El País Financiero (edición en Español)

© ATLAS VENTURES SLU, all rights reserved. Any information contained in INVESTOR TIMES is for educational and/or informational purposes only, it is not financial and/or investment advice. INVESTOR TIMES may obtain economic retribution by recommending services or products of third parties. INVESTOR TIMES does not accept, nor will it accept in the future, subsidies or funds from Governments, political parties or public institutions.

No Result
View All Result
  • Home
  • News
  • Markets
  • Investing
  • Cryptocurrencies
  • Technology

  •  EXCLUSIVE  3 Russian men are the real perpetrators behind Juicy Fields, says Glanse

     NEW  Compound Interest Calculator

     TRENDING 
    Investing in Bitcoin Investing in the Metaverse 5 reasons to invest in Amazon

© ATLAS VENTURES, all rights reserved.